Recombinant human osteogenic protein-1 induces bone formation in a chronically infected, internally stabilized segmental defect in the rat femur

被引:50
|
作者
Chen, Xinqian
Schmidt, Andrew H.
Tsukayama, Dean T.
Bourgeault, Craig A.
Lew, William D.
机构
[1] Midwest Orthopaed Res Fdn, Orthopaed Biomech Lab, Minneapolis, MN 55404 USA
[2] Hennepin Cty Med Ctr, Dept Orthopaed Surg, Minneapolis, MN 55415 USA
[3] Hennepin Cty Med Ctr, Dept Orthopaed Surg, Minneapolis, MN 55415 USA
[4] Hennepin Cty Med Ctr, Div Infect Dis, Dept Med, Minneapolis, MN 55415 USA
来源
关键词
D O I
10.2106/JBJS.E.01136
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Recombinant human osteogenic protein-1 (rhOP-1), combined with a collagen carrier, has been shown to induce new-bone formation in a variety of animal models. The purpose of the present investigation was to test the hypotheses that rhOP-1 would accelerate bone formation in an internally stabilized, chronically infected, critical-size defect in the rat femur and that this effect would be enhanced by the administration of systemic antibiotic. Methods: A 6-mm segmental defect was created surgically, stabilized with a polyacetyl plate and six Kirschner wires, and contaminated with 10(4) colony-forming units of Staphylococcus aureus in one femur in each of 168 Sprague-Dawley rats. After two weeks, these infected defects were debrided surgically and were assigned to one of six treatment groups. The defects in the thirty animals in the first group received lyophilized collagen carrier mixed with 200 mu g of rhOP-1 dissolved in buffer, the defects in the thirty animals in the second group received carrier with 20 mu g of rhOP-1 in buffer, and the defects in the twenty-four control animals in the third group received carrier mixed with buffer without rhOP-1. The last three groups were treated identically to the first three groups, except that the animals also received the antibiotic ceftriaxone for twenty-eight days after debridement. The animals were killed at two, four, eight, or twelve weeks after debridement. Newly mineralized callus within the defect, and adjacent to and bridging the outside of the defect, was assessed with use of quantitative high-resolution radiography, microcomputed tomography, torsional failure testing, and histological analysis of undecalcified sections. Results: Bacterial cultures confirmed the presence of a chronic infection during the study period in all animals. At the later time-points, significantly more newly mineralized callus was present within and adjacent to the debrided defects that had been treated with 200 mu g of rhOP-1, whereas minimal amounts of callus were present within and adjacent to the defects that had been treated without rhOP-1 and with 20 mu g of rhOP-1. At eight and twelve weeks after debridement, there was significantly more newly mineralized callus in the group that had been treated with 200 mu g of rhOP-1 with antibiotic than in the group that had been treated with 200 mu g of rhOP-1 without antibiotic (p < 0.05). At twelve weeks, the values for torque, energy to failure, and linear stiffness for femora that had been treated with 200 mu g of rhOP-1 with antibiotic were not significantly different from the values for intact, contralateral control femora, whereas the values for femora that had been treated with 200 mu g of rhOP-1 without antibiotic remained significantly lower than those for the intact, contralateral controls (p < 0.05). Conclusions: Recombinant human osteogenic protein-1 maintained its osteoinductive capability in the presence of chronic infection, and this property was enhanced by antibiotic therapy. No substantial callus formed in the infected defects without a sufficiently high dose of rhOP-1. Clinical Relevance: The treatment of an infection at the site of a fracture often necessitates removal of internal fixation. However, internal fixation is needed for fracture stability. This study presents an intervention that may accelerate fracture-healing in the presence of infection and colonized hardware, thereby permitting earlier removal of the hardware and more timely and effective treatment of the infection. Clinical Relevance: The treatment of an infection at the site of a fracture often necessitates removal of internal fixation. However, internal fixation is needed for fracture stability. This study presents an intervention that may accelerate fracture-healing in the presence of infection and colonized hardware, thereby permitting earlier removal of the hardware and more timely and effective treatment of the infection.
引用
收藏
页码:1510 / 1523
页数:14
相关论文
共 50 条
  • [1] Osteogenic protein-1 induced bone formation in an infected segmental defect in the rat femur
    Chen, XQ
    Kidder, LS
    Lew, WD
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2002, 20 (01) : 142 - 150
  • [2] Union of a chronically infected internally stabilized segmental defect in the rat femur after debridement and application of rhBMP-2 and systemic antibiotic
    Chen, Xinqian
    Schmidt, Andrew H.
    Mahjouri, Sormeh
    Polly, David W., Jr.
    Lew, William D.
    JOURNAL OF ORTHOPAEDIC TRAUMA, 2007, 21 (10) : 693 - 700
  • [3] THE EFFECT OF RECOMBINANT HUMAN OSTEOGENIC PROTEIN-1 ON HEALING OF LARGE SEGMENTAL BONE DEFECTS
    COOK, SD
    BAFFES, GC
    WOLFE, MW
    SAMPATH, TK
    RUEGER, DC
    WHITECLOUD, TS
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1994, 76A (06): : 827 - 838
  • [4] Characterization of a chronic infection in an internally-stabilized segmental defect in the rat femur
    Chen, XQ
    Tsukayama, DT
    Kidder, LS
    Bourgeault, CA
    Schmidt, AH
    Lew, WD
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2005, 23 (04) : 816 - 823
  • [5] Strut allograft healing to the femur with recombinant human osteogenic protein-1
    Cook, SD
    Barrack, RL
    Santman, M
    Patron, LP
    Salkeld, SL
    Whitecloud, TS
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2000, (381) : 47 - 57
  • [6] Stimulation of bone healing with recombinant human osteogenic protein-1
    Blokhuis, TJ
    den Boer, FC
    Bramer, JAM
    van Lingen, A
    Wippermann, B
    Bakker, FC
    Patka, P
    Haarman, HJTM
    BONE, 1999, 24 (04) : 413 - 413
  • [7] Recombinant human osteogenic protein-1 induces dentin formation: An experimental study in miniature swine
    Jepsen, S
    Albers, HK
    Fleiner, B
    Tucker, M
    Rueger, D
    JOURNAL OF ENDODONTICS, 1997, 23 (06) : 378 - 382
  • [8] Healing of segmental bone defects with granular porous hydroxyapatite augmented with recombinant human osteogenic protein-1 or autologous bone marrow
    den Boer, FC
    Wippermann, BW
    Blokhuis, TJ
    Patka, P
    Bakker, FC
    Haarman, HJTM
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2003, 21 (03) : 521 - 528
  • [9] Osteogenic protein-1 induces bone formation in the presence of bacterial infection in a rat intramuscular osteoinduction model
    Chen, XQ
    Kidder, LS
    Schmidt, AH
    Lew, WD
    JOURNAL OF ORTHOPAEDIC TRAUMA, 2004, 18 (07) : 436 - 442
  • [10] The effect of recombinant human osteogenic protein-1 (bone morphogenetic protein-7) impregnation on allografts in a canine intercalary bone defect
    Cullinane, DM
    Lietman, SA
    Inoue, N
    Deitz, LW
    Chao, EYS
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2002, 20 (06) : 1240 - 1245